The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Jan Handrick Beumer

Molecular Therapeutics/Drug Discovery Program

University of Pittsburgh Cancer Institute

Hillman Research Pavilion

Room G27D

USA

[email]@upmc.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Molecular Therapeutics/Drug Discovery Program, University of Pittsburgh Cancer Institute, Hillman Research Pavilion, Room G27D, USA. 2006 - 2011
  • Department of Pharmacy and Pharmacology, Slotervaart Hospital/The Netherlands Cancer Institute, Louwesweg 6, 1066 EC Amsterdam, Netherlands. 2005 - 2010

References

  1. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Beumer, J.H., Eiseman, J.L., Gilbert, J.A., Holleran, J.L., Yellow-Duke, A.E., Clausen, D.M., D'Argenio, D.Z., Ames, M.M., Hershberger, P.A., Parise, R.A., Bai, L., Covey, J.M., Egorin, M.J. Cancer Chemother. Pharmacol. (2011) [Pubmed]
  2. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Beumer, J.H., Franke, N.E., Tolboom, R., Buckle, T., Rosing, H., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H., van Tellingen, O. Invest. New. Drugs (2010) [Pubmed]
  3. Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). Beumer, J.H., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H., van Tellingen, O. Curr. Clin. Pharmacol (2009) [Pubmed]
  4. Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. Beumer, J.H., Eiseman, J.L., Parise, R.A., Joseph, E., Covey, J.M., Egorin, M.J. Clin. Cancer Res. (2008) [Pubmed]
  5. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Beumer, J.H., Parise, R.A., Newman, E.M., Doroshow, J.H., Synold, T.W., Lenz, H.J., Egorin, M.J. Cancer Chemother. Pharmacol. (2008) [Pubmed]
  6. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. Beumer, J.H., Eiseman, J.L., Parise, R.A., Florian, J.A., Joseph, E., D'Argenio, D.Z., Parker, R.S., Kay, B., Covey, J.M., Egorin, M.J. Cancer Chemother. Pharmacol. (2008) [Pubmed]
  7. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Beumer, J.H., Garner, R.C., Cohen, M.B., Galbraith, S., Duncan, G.F., Griffin, T., Beijnen, J.H., Schellens, J.H. Invest. New. Drugs (2007) [Pubmed]
  8. Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. Beumer, J.H., Rademaker-Lakhai, J.M., Rosing, H., Hillebrand, M.J., Bosch, T.M., Lopez-Lazaro, L., Schellens, J.H., Beijnen, J.H. Cancer Chemother. Pharmacol. (2007) [Pubmed]
  9. A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice. Beumer, J.H., Joseph, E., Egorin, M.J., Parker, R.S., D'argenio, D.Z., Covey, J.M., Eiseman, J.L. Clin. Cancer Res. (2006) [Pubmed]
  10. Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection. Beumer, J.H., Joseph, E., Egorin, M.J., Covey, J.M., Eiseman, J.L. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2006) [Pubmed]
  11. Mass balance studies, with a focus on anticancer drugs. Beumer, J.H., Beijnen, J.H., Schellens, J.H. Clin. Pharmacokinet (2006) [Pubmed]
  12. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Beumer, J.H., Natale, J.J., Lagattuta, T.F., Raptis, A., Egorin, M.J. Pharmacotherapy (2006) [Pubmed]
  13. Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice. Beumer, J.H., Eiseman, J.L., Parise, R.A., Joseph, E., Holleran, J.L., Covey, J.M., Egorin, M.J. Clin. Cancer Res. (2006) [Pubmed]
  14. Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients. Beumer, J.H., Hillebrand, M.J., Pluim, D., Rosing, H., Foley, K., Yule, S.M., Schellens, J.H., Beijnen, J.H. Invest. New. Drugs (2005) [Pubmed]
  15. Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer. Beumer, J.H., Rademaker-Lakhai, J.M., Rosing, H., Lopez-Lazaro, L., Beijnen, J.H., Schellens, J.H. Invest. New. Drugs (2005) [Pubmed]
 
WikiGenes - Universities